strontium ranelate

(redirected from Protelos)

strontium ranelate

A bone-seeking drug shown in the mid-1990s to be capable of substantially reducing the risk of fractures in post-menopausal women with OSTEOPOROSIS. The drug stimulates bone formation and reduces resorption. The usefulness of the drug was shown in a large trial, the results of which were published in January 2004. Side effects are said to be minor.
References in periodicals archive ?
Drug delivery: Strontium ranelate SKL code: 0028269 Protelos 2 G 0028270 Protelos 2G ibandronic SKL code: 0025422 Bonviva 150 mg 0,026,099 Bonviva 3 mg / 3 ml 0,202,820 Flastin 150 mg film-coated tablets 0,200,688 Gerousia 150 mg 0,161,377 Ibandronate Apotex 150mg 0,140,635 Ibandronate tablets 0,158,605 150 mg Ibandronic Acid Actavis 150 mg Ibandronic Acid Sandoz 0,187,866 150 0,198,304 mg Ibandronic Acid Stada 150 mg film-coated tablets 0,167,783 Ibandronic Acid Teva 150 mg 0,177,176 Ibandronic Acid Teva 3 mg solution for injection in pre-filled.
Les Laboratoires Servier souhaitent informer les professionnels de sante qu'au terme de la procedure de reevaluation des benefices et des risques, l'Agence Europeenne du Medicament (EMA) preconise de maintenir l'Autorisation de Mise sur le Marche (AMM) en Europe de Protelos (ranelate de strontium), avec une restriction de son indication ainsi que des mesures de suivi.
Strontium ranelate, marketed as Protelos, is a powder that is mixed with water to make a lemon-flavoured drink.
M2 PHARMA-October 24, 2011-EMA opens probe into Protelos and Osseor(C)2011 M2 COMMUNICATIONS
Strontium ranelate is marketed as Protelos or Protos in other countries, but is not currently available in the United States.
This related to the economic model used by NICE in developing final guidance issued in October 2008, on the use of drugs for both primary and secondary prevention of fractures in postmenopausal women with osteoporosis, which had the effect of restricting access to its Protelos (strontium ranelate) product.
The NHS spending watchdog Nice (National Institute for Health and Clinical Excellence) has been ordered by the High Court to rethink its decision to restrict the prescription of Protelos.
Servier, which markets the drug as Protelos, is backed in its three-day High Court battle by The Alliance for Better Bone Health and The National Osteoporosis Society.
The top dog in bone-making, however, is strontium ranelate, marketed in Europe by Servier under the name Protelos.
Next year should see the launch of a new drug, Protelos, which has been shown to actually encourage new bone growth as well as prevent bone loss.